AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|

28.6 C

New York

Wednesday, September 9, 2026

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: blood

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

OMRON Healthcare Singapore partners with bolttech and QBE to launch innovative embedded health solution

The comprehensive subscription programme offers OMRON customers in Singapore access to personalised health protection and insights SINGAPORE, July 22, 2025 /PRNewswire/ -- Global insurtech bolttech...

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Safety Shot Announces Pricing of $10.6 Million Registered Direct Offering

SCOTTSDALE, AZ, July 21, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today announced the pricing of a registered direct offering with an institutional investor for the purchase and sale of 28,648,648 shares of its common stock at a purchase price of $0.37 per share.

Semler Scientific® Announces Earnings Release Date and Live Video Webinar for Second Quarter 2025 Financial Results

CAMPBELL, Calif., July 21, 2025 /PRNewswire/ --Semler Scientific, Inc. (Nasdaq: SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve...

Summer Pitch: How to Prevent Baseball Injuries This Season

The American Academy of Orthopaedic Surgeons share expert tips to help players stay safe on the field ROSEMONT, Ill., July 21, 2025 /PRNewswire/ -- Baseball...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control

Update On Clinical Trial Milestone – CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsBlood